Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP vs Triamcinolone Acetonide in Oral Pemphigus Vulgaris
NCT02828163Phase 3Completed
- Sponsor
- Cairo University
- Start
- Jan 2016
- Primary completion
- Oct 2016
- Modality
- Adipose-derived MSCs, Bone Marrow MSCs
- Countries
- 1
01
Overview
Phase 3, double-blind trial of platelet-rich plasma in pemphigus vulgaris (PV) (2 arms), sponsored by Cairo University. Primary endpoints: Improvement of the size of oral erosions at 3 months, Improvement of the depth of oral erosions at 3 months and 1 more. Started Jan 2016; status: completed.
02
Drugs
platelet-rich plasma
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT02828163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828163.